卵巢癌组织中长链非编码RNA生长阻滞特异性抑制物5、微小RNA-205的表达及意义

Expression levels of lncRNA GAS5 and miR-205 in ovarian cancer and their clinical significances

目的分析长链非编码RNA(lncRNA)生长阻滞特异性抑制物5(GAS5)、微小RNA-205(miR-205)在卵巢癌组织中的表达及其临床意义。方法前瞻性收集2019年1月至2020年6月收治的初诊卵巢癌患者于术中取其癌组织和癌旁组织(距肿瘤边缘>2cm);采用实时荧光定量PCR法检测lncRNA GAS5、miR-205表达情况;问卷调查法统计患者临床病理资料;术后随访2年(截止时间至2022年6月),统计患者生存时间。比较癌组织和癌旁组织lncRNA GAS5、miR-205表达,并采用Pearson相关分析lncRNA GAS5与miR-205的关系;以癌组织lncRNA GAS5、miR-205表达的中位数将卵巢癌患者分为lncRNA GAS5与miR-205高表达组和低表达组,比较不同病理特征卵巢癌患者lncRNA GAS5、miR-205高表达、低表达情况;比较不同lncRNA GAS5、miR-205表达情况的卵巢癌患者生存时间。结果共82例卵巢癌患者纳入本次研究,其中2例失访,最终80例患者进入本次研究。卵巢癌组织lncRNA GAS5相对表达量小于癌旁正常组织,miR-205相对表达量大于癌旁正常组织(P<0.05);Pearson相关分析显示,卵巢癌组织中lncRNA GAS5相对表达量与miR-205相对表达量呈负相关(r=-0.606,P<0.001)。lncRNA GAS5高表达45例,低表达35例;miR-205高表达40例,低表达40例。Ⅲ~Ⅳ期、伴淋巴结转移的卵巢癌患者的卵巢组织中lncRNA GAS5低表达率高于Ⅰ~Ⅱ期、无淋巴结转移患者(P<0.05);Ⅲ~Ⅳ期、伴淋巴结转移的卵巢癌患者的卵巢组织中miR-205高表达率高于Ⅰ~Ⅱ期、无淋巴结转移患者(P<0.05)。lncRNA GAS5低表达量卵巢癌患者2年生存时间(21.50±0.89)个月,低于高表达患者(23.89±0.09)个月(χ2=5.150,P=0.023)。miR-205高表达量卵巢癌患者2年生存时间(21.71±0.79)个月,低于低表达患者(23.98±0.03)个月(χ2=6.337,P=0.012)。结论lncRNA GAS5、miR-205在卵巢癌组织表达存在一定的差异,其中lncRNA GAS5低表达,miR-205高表达,并影响卵巢癌患者的临床病理特征和预后。

Objective To measure expression levels of long non-coding RNA(lncRNA)growth arrest specific inhibitor 5(GAS5)and microRNA-205(miR-205)in ovarian cancer,and to analyze their clinical significances.Methods Intraoperatively collected cancer tissues and paracancerous tissues(>2cm away from the tumor edge)from newly diagnosed ovarian cancer patients admitted to the Fifth People’s Hospital of Chengdu from January 2019 to June 2020 were subjected to measurement of lncRNA GAS5 and miR-205 levels by real-time fluorescent quantitative PCR.The clinical and pathological data of patients were collected by questionnaire survey.Patients were followed up for 2 years,with the deadline in June 2022,and the survival time was counted.Expression levels of lncRNA GAS5 and miR-205 in ovarian cancer tissues and paracancerous tissues were compared,and the correlation was analyzed by Pearson correlation.According to the median expressions of lncRNA GAS5 and miR-205 in ovarian cancer tissues,patients were allocated to high expression group and low expression group,and their pathological characteristics and survival were compared.Results A total of 82 patients with ovarian cancer were included in this study,2 were lost to follow-up,and finally 80 eligible patients were recruited.LncRNA GAS5 was significantly downregulated,and miR-205 was significantly upregulated in ovarian cancer tissues than those in paracancerous tissues(P<0.05).Pearson correlation analysis showed that the relative expression of lncRNA GAS5 was negatively correlated with that of miR-205 in ovarian cancer(r=0.606,P<0.001).LncRNA GAS5 was highly expressed in 45 ovarian cancer patients and lowly expressed in 35 cases.MiR-205 was highly expressed in 40 ovarian cancer patients,and lowly expressed in 40 cases.The low expression rate of lncRNA GAS5 in ovarian cancer patients in stageⅢ-Ⅳ,and those with lymph node metastasis was significantly higher than that of stageⅠ-Ⅱovarian cancer patients without lymph node metastasis(P<0.05).The high expression rate of miR-205 in ovarian cancer patients in stageⅢ-Ⅳ,and those with lymph node metastasis was significantly higher than that of stageⅠ-Ⅱovarian cancer patients without lymph node metastasis(P<0.05).The 2-year survival of ovarian cancer patients with low expression of lncRNA GAS5 was significantly lower than those with high expression of lncRNA GAS5([21.50±0.89]months vs[23.89±0.09]months,χ^(2)=5.150,P=0.023).The 2-year survival of ovarian cancer patients with high expression of miR-205 was significantly lower than those with low expression of miR-205([21.71±0.79]months vs[23.98±0.03]months,χ^(2)=6.337,P=0.012).Conclusion LncRNA GAS5 and miR-205 are differentially expressed in ovarian cancer tissues.The low expression of lncRNA GAS5 and the high expression of miR-205 affect the clinicopathological characteristics and prognosis of ovarian cancer patients.